Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin

Journal of Hepatology

Volumn 64, Issue 1, 2016, Pages 29-36

  Younossi, Zobair M ^a,b   Stepanova, Maria ^b   Estep, Michael ^b   Negro, Francesco ^c   Clark, Paul J ^d   Hunt, Sharon ^a,b   Song, Qinghua ^e   Paulson, Matthew ^e   Stamm, Luisa M ^e   Brainard, Diana M ^e   Subramanian, G Mani ^e   McHutchison, John G ^e   Patel, Keyur ^f  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e GILEAD SCIENCES   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

HCV; Lipid metabolism; Ribavirin; Sofosbuvir

Indexed keywords

7 DEHYDROCHOLESTEROL; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CHOLESTEROL; DESMOSTEROL; DIHYDROLANOSTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LATHOSTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RIBAVIRIN; SOFOSBUVIR; SQUALENE STEROL; STEROL; UNCLASSIFIED DRUG; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CHRONIC HEPATITIS C; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LIPID BLOOD LEVEL; LIPOGENESIS; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; METABOLITE; METABOLOMICS; MIDDLE AGED; PATIENT SELECTION; PRIORITY JOURNAL; RELAPSE; SERUM; TREATMENT DURATION; VIROLOGY; VIRUS INTERFERENCE; VIRUS STRAIN; AGED; BIOSYNTHESIS; CLASSIFICATION; COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLISM; RECURRENT DISEASE;

ADULT; AGED; ANTIVIRAL AGENTS; CHOLESTEROL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN; SOFOSBUVIR;

EID: 84953277716     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.08.027     Document Type: Article

References (54)

1. J. Ye Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus PLoS Pathog 3 2007 e108
2. G.H. Syed, Y. Amako, and A. Siddiqui Hepatitis C virus hijacks host lipid metabolism Trends Endocrinol Metab 21 2010 33 40
3. C.I. Popescu, and J. Dubuisson Role of lipid metabolism in hepatitis C virus assembly and entry Biol Cell 102 2010 63 74
4. P. Targett-Adams, S. Boulant, M.W. Douglas, and J. McLauchlan Lipid metabolism and HCV infection Viruses 2 2010 1195 1217
5. P. Gastaminza, G. Cheng, S. Wieland, J. Zhong, W. Liao, and F.V. Chisari Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion J Virol 82 2008 2120 2129
6. E. Bugianesi, F. Salamone, and F. Negro The interaction of metabolic factors with HCV infection: does it matter? J Hepatol 56 2012 S56 S65
7. F. Negro Abnormalities of lipid metabolism in hepatitis C virus infection Gut 59 2010 1279 1287
8. P.Y. Bochud, T. Cai, K. Overbeck, M. Bochud, M. Rickenbach, J.F. Dufour, and et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C J Hepatol 51 2009 655 666
9. S.A. Harrison, E.M. Brunt, R.A. Qazi, D.A. Oliver, B.A. Neuschwander-Tetri, A.M. Di Bisceglie, and et al. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C Clin Gastroenterol Hepatol 3 2005 604 609
10. H.M. Patton, K. Patel, C. Behling, D. Bylund, L.M. Blatt, M. Vallee, and et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients J Hepatol 40 2004 484 490
11. G. Leandro, A. Mangia, J. Hui, P. Fabris, L. Rubbia-Brandt, G. Colloredo, and et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data Gastroenterology 130 2006 1636 1642
12. H. Hofer, H.C. Bankl, F. Wrba, P. Steindl-Munda, M. Peck-Radosavljevic, C. Osterreicher, and et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a Am J Gastroenterol 97 2002 2880 2885
13. L. Serfaty, T. Andreani, P. Giral, N. Carbonell, O. Chazouilleres, and R. Poupon Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C J Hepatol 34 2001 428 434
14. T. Poynard, V. Ratziu, J. McHutchison, M. Manns, Z. Goodman, S. Zeuzem, and et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C Hepatology 38 2003 75 85
15. J.M. Hui, J. Kench, G.C. Farrell, R. Lin, D. Samarasinghe, C. Liddle, and et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection J Gastroenterol Hepatol 17 2002 873 881
16. S. Mirandola, S. Realdon, J. Iqbal, M. Gerotto, F. Dal Pero, G. Bortoletto, and et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis Gastroenterology 130 2006 1661 1669
17. S.B. Kapadia, and F.V. Chisari Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids Proc Natl Acad Sci U S A 102 2005 2561 2566
18. C. Wang, M. Gale Jr., B.C. Keller, H. Huang, M.S. Brown, J.L. Goldstein, and et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication Mol Cell 18 2005 425 434
19. E.J. Zerenturk, L.J. Sharpe, E. Ikonen, and A.J. Brown Desmosterol and DHCR24: unexpected new directions for a terminal step in cholesterol synthesis Prog Lipid Res 52 2013 666 680
20. M.A. Rodgers, V.A. Villareal, E.A. Schaefer, L.F. Peng, K.E. Corey, R.T. Chung, and et al. Lipid metabolite profiling identifies desmosterol metabolism as a new antiviral target for hepatitis C virus J Am Chem Soc 134 2012 6896 6899
21. P.J. Clark, A.J. Thompson, D.M. Vock, L.E. Kratz, A.A. Tolun, A.J. Muir, and et al. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner Hepatology 56 2012 49 56
22. I.M. Jacobson, S.C. Gordon, K.V. Kowdley, E.M. Yoshida, M. Rodriguez-Torres, M.S. Sulkowski, and et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N Engl J Med 368 2013 1867 1877
23. S. Zeuzem, G.M. Dusheiko, R. Salupere, A. Mangia, R. Flisiak, R.H. Hyland, and et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3 N Engl J Med 370 2014 1993 2001
24. E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-Torres, T. Hassanein, S.C. Gordon, and et al. Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
25. L. Castera, J. Vergniol, J. Foucher, B. Le Bail, E. Chanteloup, M. Haaser, and et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C Gastroenterology 128 2005 343 350
26. T. Poynard, F. Imbert-Bismut, M. Munteanu, D. Messous, R.P. Myers, D. Thabut, and et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C Comp Hepatol 3 2004 8
27. R.I. Kelley Diagnosis of Smith-Lemli-Opitz syndrome by gas chromatography/mass spectrometry of 7-dehydrocholesterol in plasma, amniotic fluid and cultured skin fibroblasts Clin Chim Acta 236 1995 45 58
28. M.F. Bassendine, D.A. Sheridan, D.J. Felmlee, S.H. Bridge, G.L. Toms, and R.D. Neely HCV and the hepatic lipid pathway as a potential treatment target J Hepatol 55 2011 1428 1440
29. P. Andre, F. Komurian-Pradel, S. Deforges, M. Perret, J.L. Berland, M. Sodoyer, and et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles J Virol 76 2002 6919 6928
30. B.D. Lindenbach, M.J. Evans, A.J. Syder, B. Wolk, T.L. Tellinghuisen, C.C. Liu, and et al. Complete replication of hepatitis C virus in cell culture Science 309 2005 623 626
31. D.A. Price, M.F. Bassendine, S.M. Norris, C. Golding, G.L. Toms, M.L. Schmid, and et al. Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection Gut 55 2006 715 718
32. S. Liu, K.D. McCormick, W. Zhao, T. Zhao, D. Fan, and T. Wang Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding Hepatology 56 2012 484 491
33. K.S. Chang, J. Jiang, Z. Cai, and G. Luo Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture J Virol 81 2007 13783 13793
34. O. Chiba-Falek, C. Linnertz, J. Guyton, S.D. Gardner, A.D. Roses, J.J. McCarthy, and et al. Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection Hum Genet 131 2012 1911 1920
35. C. Fabris, C. Vandelli, P. Toniutto, R. Minisini, C. Colletta, E. Falleti, and et al. Apolipoprotein E genotypes modulate fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases J Gastroenterol Hepatol 26 2011 328 333
36. S.R. Shah, K. Patel, P. Marcellin, G.R. Foster, M. Manns, S. Kottilil, and et al. Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3 Clin Gastroenterol Hepatol 9 2011 688 693
37. M.C. Ryan, P.V. Desmond, J.L. Slavin, and M. Congiu Expression of genes involved in lipogenesis is not increased in patients with HCV genotype 3 in human liver J Viral Hepat 18 2011 53 60
38. A.I. Su, J.P. Pezacki, L. Wodicka, A.D. Brideau, L. Supekova, R. Thimme, and et al. Genomic analysis of the host response to hepatitis C virus infection Proc Natl Acad Sci U S A 99 2002 15669 15674
39. J. Ye, C. Wang, R. Sumpter Jr., M.S. Brown, J.L. Goldstein, and M. Gale Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation Proc Natl Acad Sci U S A 100 2003 15865 15870
40. M. Ikeda, K. Abe, M. Yamada, H. Dansako, K. Naka, and N. Kato Different anti-HCV profiles of statins and their potential for combination therapy with interferon Hepatology 44 2006 117 125
41. J.G. O'Leary, J.L. Chan, C.M. McMahon, and R.T. Chung Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial Hepatology 45 2007 895 898
42. K. Patel, R. Jhaveri, J. George, G. Qiang, C. Kenedi, K. Brown, and et al. Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C J Viral Hepat 18 2011 331 337
43. L.J. Sharpe, and A.J. Brown Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) J Biol Chem 288 2013 18707 18715
44. J.E. Lambert, V.G. Bain, E.A. Ryan, A.B. Thomson, and M.T. Clandinin Elevated lipogenesis and diminished cholesterol synthesis in patients with hepatitis C viral infection compared to healthy humans Hepatology 57 2013 1697 1704
45. A.D. Nguyen, J.G. McDonald, R.K. Bruick, and R.A. DeBose-Boyd Hypoxia stimulates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase through accumulation of lanosterol and hypoxia-inducible factor-mediated induction of insigs J Biol Chem 282 2007 27436 27446
46. C.Y. Park, H.J. Jun, T. Wakita, J.H. Cheong, and S.B. Hwang Hepatitis C virus nonstructural 4B protein modulates sterol regulatory element-binding protein signaling via the AKT pathway J Biol Chem 284 2009 9237 9246
47. G. Waris, D.J. Felmlee, F. Negro, and A. Siddiqui Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress J Virol 81 2007 8122 8130
48. M. Saito, M. Kohara, and K. Tsukiyama-Kohara Hepatitis C virus promotes expression of the 3beta-hydroxysterol delta24-reductase through Sp1 J Med Virol 84 2012 733 746
49. T. Takano, K. Tsukiyama-Kohara, M. Hayashi, Y. Hirata, M. Satoh, Y. Tokunaga, and et al. Augmentation of DHCR24 expression by hepatitis C virus infection facilitates viral replication in hepatocytes J Hepatol 55 2011 512 521
50. S.K. Bose, H. Kim, K. Meyer, N. Wolins, N.O. Davidson, and R. Ray Forkhead box transcription factor regulation and lipid accumulation by hepatitis C virus J Virol 88 2014 4195 4203
51. J.M. Lecerf, and M. de Lorgeril Dietary cholesterol: from physiology to cardiovascular risk Br J Nutr 106 2011 6 14
52. T. Sudhop, Y. Sahin, B. Lindenthal, C. Hahn, C. Luers, H.K. Berthold, and et al. Comparison of the hepatic clearances of campesterol, sitosterol, and cholesterol in healthy subjects suggests that efflux transporters controlling intestinal sterol absorption also regulate biliary secretion Gut 51 2002 860 863
53. H.J. Kempen, J.F. Glatz, J.A. Gevers Leuven, H.A. van der Voort, and M.B. Katan Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans J Lipid Res 29 1988 1149 1155
54. J.H. Li, X.Q. Lao, H.L. Tillmann, J. Rowell, K. Patel, A. Thompson, and et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection Hepatology 51 2010 1904 1911